BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38316885)

  • 1. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer.
    Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
    Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients.
    Bai WD; Liu JY; Li M; Yang X; Wang YL; Wang GJ; Li SC
    World J Oncol; 2022 Oct; 13(5):299-310. PubMed ID: 36406193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
    Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
    BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of single-cell and bulk RNA seq to reveal the prognostic model and tumor microenvironment remodeling mechanisms of cuproptosis-related genes in colorectal cancer.
    Chu B; Wang Y; Yang J; Dong B
    Aging (Albany NY); 2023 Dec; 15(23):14422-14444. PubMed ID: 38078879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
    Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
    Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cuproptosis-Related Gene
    Fang Z; Wang W; Liu Y; Hua J; Liang C; Liu J; Zhang B; Shi S; Yu X; Meng Q; Xu J
    Curr Oncol; 2023 Mar; 30(3):2997-3019. PubMed ID: 36975441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma.
    Guo JS; Ding H; Wu PY; Xin ZY; Li JX; Jo HS; Ma ZH
    Chin Med Sci J; 2023 Sep; 38(3):191-205. PubMed ID: 37503721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
    Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
    Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
    Li Y; Zeng X
    Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
    [No Abstract]   [Full Text] [Related]  

  • 13. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma.
    Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B
    J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
    Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
    BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
    Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
    Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis identifies cuproptosis-related gene DLAT and its competing endogenous RNAs network to predict the prognosis of pancreatic adenocarcinoma patients.
    Zhou C; Jin L; Yu J; Gao Z
    Medicine (Baltimore); 2024 Mar; 103(9):e37322. PubMed ID: 38428843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.